<p><em><strong>治疗两年后，接受 GelrinC 治疗的患者展示了类似于天然透明软骨的分层软骨结构——被广泛认为是持久关节功能的金标准</strong></em></p>
<p><em><strong>这种在软骨修复中罕见的结果表明真正的生物软骨再生，而不仅仅是缺损填充</strong></em></p>
<p><em><strong>与传统支架不同，GelrinC 限制了纤维组织的过度生长，支持更顺畅的关节运动并保持自然生物力学</strong></em></p>
<p>Regentis Biomaterials Ltd.（&#34;Regentis&#34;或&#34;公司&#34;）（纽约证券交易所：RGNT）是一家专注于创新组织修复解决方案的再生医学公司，今天宣布了来自其成功完成的欧洲临床试验 GelrinC®的新长期影像数据，显示再生软骨的内部结构组织与健康的天然透明软骨非常相似。</p>
<p>这些数据发表在同行评审的期刊《Cartilage》上，基于对接受 GelrinC®治疗膝关节局部软骨缺损患者的先进 MRI 分析。MRI 结果显示，组织结构随着时间的推移逐渐改善，表明再生软骨在植入后持续成熟。到 24 个月时，修复的组织展现出与天然透明软骨相当的分层结构，后者被广泛认为是长期关节耐久性和功能的金标准。这种结构组织的程度表明 GelrinC®支持真正生物质量的软骨形成，而不是纤维或瘢痕样修复组织。</p>
<p>该分析由维也纳大学的 Siegfried Trattnig 教授及其同事进行，他们是软骨 MRI 成像领域的全球领导者，使用了美国 FDA 和欧洲 EMA 监管机构认可的验证方法，进一步增强了研究结果的转化和监管相关性。</p>
<p>&#34;这些数据表明 GelrinC®有助于再生与健康天然组织结构相似的软骨，远远超出了简单填补缺损的范围，&#34;Regentis 的执行主席 Ehud Geller 博士表示。&#34;这些发现强化了 GelrinC®提供真实、持久软骨再生的潜力，并支持我们正在推进的美国 FDA 第三阶段研究以及在欧洲的商业化努力，GelrinC®已获得 CE 标志批准。&#34;</p>
<p>在天然软骨中，不同层次的特征由不同的胶原蛋白类型构成——那些与健康透明软骨相关的和那些与纤维修复相关的。值得注意的是，经过 GelrinC®治疗后再生的软骨展现出相同的胶原蛋白相关分层模式，表明该植入物创造了一个有利于真实软骨恢复的生物环境。</p>
<p>GelrinC®的可注射植入物精确地模塑成软骨缺损，形成与周围组织的无缝界面——这是长期整合和机械稳定性的关键因素。与传统支架不同，GelrinC®已被证明限制了纤维组织的过度生长，帮助保持顺畅的关节运动和自然生物力学。其独特的表面化学和结构设计旨在引导细胞组织，不仅塑造愈合，还影响再生软骨的质量和功能。</p>
<p><strong>GelrinC®的软骨再生</strong></p>
<p>这些连续的 MRI 图像展示了 GelrinC®治疗后软骨的逐渐再生和成熟。</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/imagelibrary/a3f54bc7-9dcb-4154-b7e6-0d9ea571a89c/1129098/picture3.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/imagelibrary/a3f54bc7-9dcb-4154-b7e6-0d9ea571a89c/1129098/picture3.png"/></p>
<p>治疗一周后，缺损区域清晰可见。随着时间的推移，图像展示了逐渐的组织形成和结构组织。到 12 个月时，再生的软骨显示出显著改善，而到 24 个月时，缺损被结构良好的软骨组织填充，结构和质量与天然软骨相似，反映在高 MOCART 评分上。</p>
<p>这一缓慢而持续的成熟过程表明 GelrinC®支持持久的软骨再生，组织质量在初始愈合阶段之后仍在持续改善。</p>
<p><strong>关于 GelrinC®</strong></p>
<p>Regentis 的主打产品 GelrinC®是一种无细胞、现成的水凝胶同步降解和可吸收植入物，用于治疗膝关节局部软骨的疼痛损伤。作为一种创新的再生医学产品，GelrinC®提供了前所未有的解决方案，使外科医生和支付方能够使用现成的、简单易行、可靠且具有成本效益的程序，为患者提供一次 10 分钟的手术，基于迄今为止的临床研究结果，实现更快的恢复、持续的疼痛缓解和超过 4 年的功能改善。目前市场上没有有效的现成治疗膝关节局部软骨缺损的产品。GelrinC®已在欧盟获得 CE 标志批准，并正在进行一项关键的美国食品药品监督管理局（FDA）研究，目前已完成超过 50% 的入组。</p>
<p><strong>关于 Regentis Biomaterials</strong></p>
<p>Regentis Biomaterials Ltd 是一家再生医学公司，致力于开发创新的组织修复解决方案，以恢复健康并提高生活质量。Regentis 的 Gelrin 平台技术最初专注于骨科治疗，基于同步、可降解的水凝胶植入物，能够再生受损或患病的组织，包括发炎的软骨和骨骼。Regentis 的主打产品 GelrinC®是一种无细胞、现成的水凝胶，在膝关节中被降解和吸收，允许周围细胞以受控和同步的方式再生软骨。GelrinC®旨在解决美国每年约 470,000 例膝关节软骨修复的市场需求，目前没有现成的治疗可用。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含 “前瞻性声明”，这些声明面临重大风险和不确定性。本新闻稿中包含的所有声明，除了历史事实的陈述外，均为前瞻性声明。本新闻稿中的前瞻性声明可以通过使用诸如 “预期”、“相信”、“考虑”、“可能”、“估计”、“期望”、“打算”、“寻求”、“或许”、“计划”、“潜在”、“预测”、“项目”、“目标”、“旨在”、“应该”、“将会” 或 “会” 的否定形式或其他类似表达来识别，尽管并非所有前瞻性声明都包含这些词，并且包括对 Regentis 市场定位的看法。前瞻性声明基于 Regentis 当前的预期，并且面临固有的不确定性、风险和假设，这些因素难以预测。此外，某些前瞻性声明基于对未来事件的假设，这些假设可能并不准确。可能影响未来结果并导致这些前瞻性声明不准确的因素包括但不限于：我们的临床试验能否证明 GelrinC 或任何未来产品候选者的安全性和有效性，以及其他积极结果；我们临床前研究和临床试验的时间安排和重点，以及来自这些研究和试验的数据报告；GelrinC 或任何未来产品候选者的市场机会规模，包括我们对患有我们所针对疾病的患者数量的估计；我们准确识别产品候选者需求的能力；竞争疗法的成功，这些疗法可能已经或将来可能可用；我们产品候选者的有益特性、安全性、有效性和治疗效果；我们获得 GelrinC 或任何未来产品候选者的 FDA 批准以及获得和维持监管批准的能力；我们获得医疗界和第三方支付方对 GelrinC 或任何未来产品候选者的市场接受度的能力；我们关于进一步开发 GelrinC 或任何未来产品候选者的计划，包括我们可能追求的其他疾病状态或适应症；美国及其他地区现有的法规和监管发展；我们获得或保护知识产权的计划和能力，包括在可用情况下延长专利期限的能力，以及避免侵犯他人知识产权的能力；需要招聘额外人员以及我们吸引和留住这些人员的能力；我们对费用、未来收入、资本需求和额外融资需求的估计；我们对第三方的依赖；我们的财务表现以及我们偿还贷款和债务的能力；以及我们在可能进入的任何合作、许可或其他安排中谈判有利条款的能力，以及履行我们在此类合作中的义务。有关影响 Regentis 的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于在与 SEC 提交的公开发行最终招股说明书中详细列出的 “风险因素” 部分。本公告中包含的前瞻性声明截至本日期作出，Regentis 没有义务更新此类信息，除非适用法律要求。</p>
<p><strong>联系方式：</strong></p>
<p><strong>acarlquist@medicavp.com</strong></p>
<p><strong>来源：</strong> Regentis Biomaterials Ltd.</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyOTA5OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyOTA5OA"/></p>

RGNT

<p>Regentis Biomaterials Ltd. 宣布其 GelrinC® 治疗在再生与天然透明软骨相似的软骨方面显示出显著的长期成功，这一结果得到了欧洲临床试验的 MRI 结果的确认。治疗后两年，患者表现出分层的软骨结构，表明是真正的生物再生，而不仅仅是缺损填充。GelrinC® 限制了纤维组织的过度生长，支持自然关节功能。这些发现发表在《软骨》期刊上，增强了该产品在持久软骨修复方面的潜力，并支持正在进行的 FDA 研究和在欧洲的商业化努力，后者已获得 CE 标志认证</p>

<p><em><strong>2 years after treatment, GelrinC-treated patients demonstrated layered cartilage architecture similar to native hyaline cartilage - widely regarded as the gold standard for durable joint function</strong></em></p>
<div class="lb-trans"><p><em><strong>治疗两年后，接受 GelrinC 治疗的患者展示了类似于天然透明软骨的分层软骨结构——被广泛认为是持久关节功能的金标准</strong></em></p>
</div><p><em><strong>This rare outcome in cartilage repair suggests true biological cartilage regeneration, not merely defect filling</strong></em></p>
<div class="lb-trans"><p><em><strong>这种在软骨修复中罕见的结果表明真正的生物软骨再生，而不仅仅是缺损填充</strong></em></p>
</div><p><em><strong>Unlike traditional scaffolds, GelrinC limits fibrotic tissue overgrowth, supporting smoother joint motion and preserving natural biomechanics</strong></em></p>
<div class="lb-trans"><p><em><strong>与传统支架不同，GelrinC 限制了纤维组织的过度生长，支持更顺畅的关节运动并保持自然生物力学</strong></em></p>
</div><p>Regentis Biomaterials Ltd., (&#34;Regentis&#34; or the &#34;Company&#34;) (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced new long-term imaging data from its successfully completed European clinical trial of GelrinC®, demonstrating that regenerated cartilage exhibits internal structural organization closely resembling healthy, native hyaline cartilage.</p>
<div class="lb-trans"><p>Regentis Biomaterials Ltd.（&#34;Regentis&#34;或&#34;公司&#34;）（纽约证券交易所：RGNT）是一家专注于创新组织修复解决方案的再生医学公司，今天宣布了来自其成功完成的欧洲临床试验 GelrinC®的新长期影像数据，显示再生软骨的内部结构组织与健康的天然透明软骨非常相似。</p>
</div><p>The data, published in the peer-reviewed journal <em>Cartilage</em>, are based on an advanced MRI analysis of patients treated with GelrinC® for focal cartilage defects in the knee. MRI findings revealed progressive improvement in tissue organization over time, indicating continued maturation of the regenerated cartilage well beyond implantation. By 24 months, the repaired tissue exhibited a layered architecture comparable to native hyaline cartilage, which is widely regarded as the gold standard for long-term joint durability and function. This degree of structural organization suggests that GelrinC® supports the formation of cartilage with true biological quality, rather than fibrotic or scar-like repair tissue.</p>
<div class="lb-trans"><p>这些数据发表在同行评审的期刊《Cartilage》上，基于对接受 GelrinC®治疗膝关节局部软骨缺损患者的先进 MRI 分析。MRI 结果显示，组织结构随着时间的推移逐渐改善，表明再生软骨在植入后持续成熟。到 24 个月时，修复的组织展现出与天然透明软骨相当的分层结构，后者被广泛认为是长期关节耐久性和功能的金标准。这种结构组织的程度表明 GelrinC®支持真正生物质量的软骨形成，而不是纤维或瘢痕样修复组织。</p>
</div><p>The analysis was conducted by Prof. Siegfried Trattnig of Vienna University and his colleagues, global leaders in cartilage MRI imaging, using validated methodologies accepted by both U.S. FDA and Europe's EMA regulators, further strengthening the translational and regulatory relevance of the findings.</p>
<div class="lb-trans"><p>该分析由维也纳大学的 Siegfried Trattnig 教授及其同事进行，他们是软骨 MRI 成像领域的全球领导者，使用了美国 FDA 和欧洲 EMA 监管机构认可的验证方法，进一步增强了研究结果的转化和监管相关性。</p>
</div><p>&#34;This data shows that GelrinC® helps regenerate cartilage that mirrors the structure of healthy, native tissue, going far beyond simply filling a defect,&#34; said Dr. Ehud Geller, Executive Chairman of Regentis. &#34;These findings reinforce GelrinC®'s potential to deliver authentic, long-lasting cartilage regeneration and support our advancing Phase III U.S. FDA study and our commercialization efforts in Europe where GelrinC® has CE Mark approval.&#34;</p>
<div class="lb-trans"><p>&#34;这些数据表明 GelrinC®有助于再生与健康天然组织结构相似的软骨，远远超出了简单填补缺损的范围，&#34;Regentis 的执行主席 Ehud Geller 博士表示。&#34;这些发现强化了 GelrinC®提供真实、持久软骨再生的潜力，并支持我们正在推进的美国 FDA 第三阶段研究以及在欧洲的商业化努力，GelrinC®已获得 CE 标志批准。&#34;</p>
</div><p>In native cartilage, distinct layers are characterized by different collagen types-those associated with healthy hyaline cartilage and those linked to fibrotic repair. Remarkably, cartilage regenerated following GelrinC® treatment exhibited the same collagen-related layered pattern, indicating that the implant creates a biological environment conducive to authentic cartilage restoration.</p>
<div class="lb-trans"><p>在天然软骨中，不同层次的特征由不同的胶原蛋白类型构成——那些与健康透明软骨相关的和那些与纤维修复相关的。值得注意的是，经过 GelrinC®治疗后再生的软骨展现出相同的胶原蛋白相关分层模式，表明该植入物创造了一个有利于真实软骨恢复的生物环境。</p>
</div><p>GelrinC®'s injectable implant molds precisely to the cartilage defect, forming a seamless interface with surrounding tissue-an essential factor for long-term integration and mechanical stability. Unlike traditional scaffolds, GelrinC® has been shown to limit fibrotic tissue overgrowth, helping preserve smooth joint motion and natural biomechanics. Its unique surface chemistry and structural design are engineered to guide cellular organization, shaping not only healing but the quality and function of the regenerated cartilage.</p>
<div class="lb-trans"><p>GelrinC®的可注射植入物精确地模塑成软骨缺损，形成与周围组织的无缝界面——这是长期整合和机械稳定性的关键因素。与传统支架不同，GelrinC®已被证明限制了纤维组织的过度生长，帮助保持顺畅的关节运动和自然生物力学。其独特的表面化学和结构设计旨在引导细胞组织，不仅塑造愈合，还影响再生软骨的质量和功能。</p>
</div><p><strong>Cartilage Regeneration with GelrinC®</strong></p>
<div class="lb-trans"><p><strong>GelrinC®的软骨再生</strong></p>
</div><p>These sequential MRI images illustrate the gradual regeneration and maturation of cartilage following GelrinC® treatment.</p>
<div class="lb-trans"><p>这些连续的 MRI 图像展示了 GelrinC®治疗后软骨的逐渐再生和成熟。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/imagelibrary/a3f54bc7-9dcb-4154-b7e6-0d9ea571a89c/1129098/picture3.png" alt="" original-src="https://app.accessnewswire.com/imagelibrary/a3f54bc7-9dcb-4154-b7e6-0d9ea571a89c/1129098/picture3.png"/></p>
<p>One week after treatment, the defect area is clearly visible. Over time, the images demonstrate progressive tissue formation and structural organization. By 12 months, the regenerated cartilage shows substantial improvement, and by 24 months, the defect is filled with well-organized cartilage tissue that closely resembles native cartilage in structure and quality, as reflected by the high MOCART score.</p>
<div class="lb-trans"><p>治疗一周后，缺损区域清晰可见。随着时间的推移，图像展示了逐渐的组织形成和结构组织。到 12 个月时，再生的软骨显示出显著改善，而到 24 个月时，缺损被结构良好的软骨组织填充，结构和质量与天然软骨相似，反映在高 MOCART 评分上。</p>
</div><p>This slow and continuous maturation process suggests that GelrinC® supports durable cartilage regeneration, with tissue quality that continues to improve well beyond the initial healing phase.</p>
<div class="lb-trans"><p>这一缓慢而持续的成熟过程表明 GelrinC®支持持久的软骨再生，组织质量在初始愈合阶段之后仍在持续改善。</p>
</div><p><strong>About GelrinC®</strong></p>
<div class="lb-trans"><p><strong>关于 GelrinC®</strong></p>
</div><p>Regentis' lead product, GelrinC®, is a cell-free, off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. As an innovative regenerative medical product, GelrinC® offers an unprecedented solution that gives surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 4 years, based on clinical study results to date. No effective off-the-shelf, ready to use treatment for focal knee cartilage defects is currently available on the market. GelrinC® has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over 50% enrollment.</p>
<div class="lb-trans"><p>Regentis 的主打产品 GelrinC®是一种无细胞、现成的水凝胶同步降解和可吸收植入物，用于治疗膝关节局部软骨的疼痛损伤。作为一种创新的再生医学产品，GelrinC®提供了前所未有的解决方案，使外科医生和支付方能够使用现成的、简单易行、可靠且具有成本效益的程序，为患者提供一次 10 分钟的手术，基于迄今为止的临床研究结果，实现更快的恢复、持续的疼痛缓解和超过 4 年的功能改善。目前市场上没有有效的现成治疗膝关节局部软骨缺损的产品。GelrinC®已在欧盟获得 CE 标志批准，并正在进行一项关键的美国食品药品监督管理局（FDA）研究，目前已完成超过 50% 的入组。</p>
</div><p><strong>About Regentis Biomaterials</strong></p>
<div class="lb-trans"><p><strong>关于 Regentis Biomaterials</strong></p>
</div><p>Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC®, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC® aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.</p>
<div class="lb-trans"><p>Regentis Biomaterials Ltd 是一家再生医学公司，致力于开发创新的组织修复解决方案，以恢复健康并提高生活质量。Regentis 的 Gelrin 平台技术最初专注于骨科治疗，基于同步、可降解的水凝胶植入物，能够再生受损或患病的组织，包括发炎的软骨和骨骼。Regentis 的主打产品 GelrinC®是一种无细胞、现成的水凝胶，在膝关节中被降解和吸收，允许周围细胞以受控和同步的方式再生软骨。GelrinC®旨在解决美国每年约 470,000 例膝关节软骨修复的市场需求，目前没有现成的治疗可用。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains &#34;forward-looking statements&#34; that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as &#34;anticipate,&#34; &#34;believe,&#34; &#34;contemplate,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;seek,&#34; &#34;may,&#34; &#34;might,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;target,&#34; &#34;aim,&#34; &#34;should,&#34; &#34;will&#34; &#34;would,&#34; or the negative of these words or other similar expressions, although not all forward-looking statements contain these words, and include beliefs regarding Regentis' market positioning. Forward-looking statements are based on Regentis' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the ability of our clinical trials to demonstrate safety and efficacy of GelrinC or any future product candidate, and other positive results; the timing and focus of our preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for of GelrinC or any future product candidate, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to accurately identify demand for product candidates; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain FDA approval for of GelrinC or any future product candidate and obtain and maintain regulatory approval; our ability to obtain market acceptance of of GelrinC or any future product candidate from the medical community and third-party payors; our plans relating to the further development of GelrinC or any future product candidate, including additional disease states or indications we may pursue; existing regulations and regulatory developments in the United States and other jurisdictions; our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our dependence on third parties; our financial performance and our ability to repay our loans and debts; and our ability to negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations. For a more detailed description of the risks and uncertainties affecting Regentis, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission (&#34;SEC&#34;), including, but not limited to, the risks detailed in the section titled &#34;Risk Factors&#34; in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Regentis undertakes no duty to update such information except as required under applicable law.</p>
<div class="lb-trans"><p>本新闻稿包含 “前瞻性声明”，这些声明面临重大风险和不确定性。本新闻稿中包含的所有声明，除了历史事实的陈述外，均为前瞻性声明。本新闻稿中的前瞻性声明可以通过使用诸如 “预期”、“相信”、“考虑”、“可能”、“估计”、“期望”、“打算”、“寻求”、“或许”、“计划”、“潜在”、“预测”、“项目”、“目标”、“旨在”、“应该”、“将会” 或 “会” 的否定形式或其他类似表达来识别，尽管并非所有前瞻性声明都包含这些词，并且包括对 Regentis 市场定位的看法。前瞻性声明基于 Regentis 当前的预期，并且面临固有的不确定性、风险和假设，这些因素难以预测。此外，某些前瞻性声明基于对未来事件的假设，这些假设可能并不准确。可能影响未来结果并导致这些前瞻性声明不准确的因素包括但不限于：我们的临床试验能否证明 GelrinC 或任何未来产品候选者的安全性和有效性，以及其他积极结果；我们临床前研究和临床试验的时间安排和重点，以及来自这些研究和试验的数据报告；GelrinC 或任何未来产品候选者的市场机会规模，包括我们对患有我们所针对疾病的患者数量的估计；我们准确识别产品候选者需求的能力；竞争疗法的成功，这些疗法可能已经或将来可能可用；我们产品候选者的有益特性、安全性、有效性和治疗效果；我们获得 GelrinC 或任何未来产品候选者的 FDA 批准以及获得和维持监管批准的能力；我们获得医疗界和第三方支付方对 GelrinC 或任何未来产品候选者的市场接受度的能力；我们关于进一步开发 GelrinC 或任何未来产品候选者的计划，包括我们可能追求的其他疾病状态或适应症；美国及其他地区现有的法规和监管发展；我们获得或保护知识产权的计划和能力，包括在可用情况下延长专利期限的能力，以及避免侵犯他人知识产权的能力；需要招聘额外人员以及我们吸引和留住这些人员的能力；我们对费用、未来收入、资本需求和额外融资需求的估计；我们对第三方的依赖；我们的财务表现以及我们偿还贷款和债务的能力；以及我们在可能进入的任何合作、许可或其他安排中谈判有利条款的能力，以及履行我们在此类合作中的义务。有关影响 Regentis 的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于在与 SEC 提交的公开发行最终招股说明书中详细列出的 “风险因素” 部分。本公告中包含的前瞻性声明截至本日期作出，Regentis 没有义务更新此类信息，除非适用法律要求。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p><strong>acarlquist@medicavp.com</strong></p>
<div class="lb-trans"><p><strong>acarlquist@medicavp.com</strong></p>
</div><p><strong>SOURCE:</strong> Regentis Biomaterials Ltd.</p>
<div class="lb-trans"><p><strong>来源：</strong> Regentis Biomaterials Ltd.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyOTA5OA" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1129098"/></p>

Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method | RGNT Stock News

Regentis 的 GelrinC 在膝关节修复中展示了再生类似天然软骨结构的突破，MRI 结果已通过验证且被监管机构接受的方法确认 | RGNT 股票新闻